Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dow gains US patent for Enlist maize

Dow AgroSciences has received a US patent for its genetically modified herbicide-tolerant Enlist maize (DAS40278). The patent (8,598,413) covers maize with tolerance to aryloxyphenoxy propionate herbicides, and 2,4-D and other phenoxy herbicides. It also includes stacking with other traits. Enlist maize allows the application of herbicides to control grasses and broadleaf weeds. Dow was previously granted a patent (7,838,733) covering tolerance to 2,4-D in maize and other monocotyledonous crops and another (8,283,522) covering an aryloxyalkanoate dioxygenase gene and enzyme conferring tolerance to 2,4-D and pyridyloxyacetate herbicides in dicotyledonous plants such as soybeans and cotton (Agrow No 650, p 21). The company plans to introduce Enlist maize in the US in 2015 subject to regulatory approvals. Commercialisation has been delayed by the USDA's call for an environmental impact statement (Agrow No 664, p 14).

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG000799

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel